Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Velasco, Román Pérez ^a   Praditsitthikorn, Naiyana ^a   Wichmann, Kamonthip ^a   Mohara, Adun ^a   Kotirum, Surachai ^a   Tantivess, Sripen ^a   Vallenas, Constanza ^b   Harmanci, Hande ^b   Teerawattananon, Yot ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROL STRATEGY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA VACCINATION; PANDEMIC INFLUENZA; PRACTICE GUIDELINE; REVIEW; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; DISASTER PLANNING; ECONOMICS; INFECTIOUS DISEASE MEDICINE; INFLUENZA; INFLUENZA VIRUS A H1N1; INFORMATION PROCESSING; METABOLISM; METHODOLOGY; PANDEMIC; PUBLIC HEALTH; STATISTICAL ANALYSIS; STATISTICAL MODEL;

COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DISASTER PLANNING; HUMANS; INFECTIOUS DISEASE MEDICINE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MODELS, ECONOMIC; PANDEMICS; PUBLIC HEALTH;

EID: 84857663305     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030333     Document Type: Review

References (58)

1. World Health Organization (2009) Pandemic influenza preparedness and response: a WHO guidance document Geneva, Switzerland World Health Organization.
2. Girard MP, Tam JS, Assossou OM, Kieny MP, (2010) The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 28: 4895-4902.
3. Congressional Budget Office of the US (2006) A potential influenza pandemic: possible macroeconomic effects and policy issues Washington DC, US US Congress.
4. Jonung L, Roeger W, (2006) The macroeconomic effects of a pandemic in Europe: a model-based assessment Brussels, Belgium European Commission, Directorate-General for Economic and Financial Affairs.
5. Meltzer MI, Cox NJ, Fukuda K, (1999) The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 5: 659-671.
6. Teerawattananon Y, Russell S, Mugford M, (2007) A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers?. Pharmacoeconomics 25: 467-479.
7. Cooper NCD, Abrams K, Mugford M, Sutton A, (2005) Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy 10: 245-250.
8. World Bank, (2011) Data: how we classify countries Washington DC, US The World Bank Group.
9. Lugnér AK, van Boven M, de Vries R, Postma MJ, Wallinga J, (2010) Cost-effectiveness of vaccination against pandemic influenza in European countries: the role of immunity in the elderly. In: Lugner AK, editors. Cost-effectiveness of controlling infectious diseases from a public health perspective Groningen, Netherlands University of Groningen pp. 15-31.
10. Carrasco LR, Lee VJ, Chen MI, Matchar DB, Thompson JP, et al. (2011) Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective. J R Soc Interface 8: 1307-1313.
11. Andradóttir S, Chiu W, Goldsman D, Lee ML, Tsui KL, et al. (2011) Reactive strategies for containing developing outbreaks of pandemic influenza. BMC Public Health 11: S1.
12. Baguelin M, Hoek AJ, Jit M, Flasche S, White PJ, et al. (2010) Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 28: 2370-2384.
13. Balicer RD, Huerta M, Davidovitch N, Grotto I, (2005) Cost-benefit of stockpiling drugs for influenza pandemic. Emerg Infect Dis 11: 1280-1282.
14. Beigi RH, Wiringa AE, Bailey RR, Assi TM, Lee BY, (2009) Economic value of seasonal and pandemic influenza vaccination during pregnancy. Clin Infect Dis 49: 1784-1792.
15. Brouwers L, Cakici B, Camitz M, Tegnell A, Boman M, (2009) Economic consequences to society of pandemic H1N1 influenza 2009- preliminary results for Sweden. Euro Surveill 14: pii: 19333.
16. Brown ST, Tai JH, Bailey RR, Cooley PC, Wheaton WD, et al. (2011) Would school closure for the 2009 H1N1 influenza epidemic have been worth the cost?: a computational simulation of Pennsylvania. BMC Public Health 11: 353.
17. Brunovský PŠD, Somorčík J, Hroncová D, Pospíšilová K, (2009) Socio-economic impacts of influenza pandemics mitigation scenarios in Slovakia. Ekon Cas 57: 163-178.
18. Dan YY, Tambyah PA, Sim J, Lim J, Hsu LY, et al. (2009) Cost-effectiveness analysis of hospital infection control response to an epidemic respiratory virus threat. Emerg Infect Dis 15: 1909-1916.
19. Deuffic-Burban S, Lenne X, Dervaux B, Julien P, Lemaire X, et al. (2009) Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: clinical and economic impact. PLoS Curr 1: RRN1121.
20. Doyle A, Bonmarin I, Lévy-Bruhl D, Le Strat Y, Desenclos JC, (2006) Influenza pandemic preparedness in France: modelling the impact of interventions. J Epidemiol Community Health 60: 399-404.
21. Durbin A, Corallo AN, Wibisono TG, Aleman DM, Schwartz B, et al. (2011) A cost effectiveness analysis of the H1N1 vaccine strategy for Ontario, Canada. J Infect Dis Immun 3: 40-49.
22. Epstein JM, Goedecke DM, Yu F, Morris RJ, Wagener DK, et al. (2007) Controlling pandemic flu: the value of international air travel restrictions. PLoS One 2: e401.
23. González-Canudas J, Iglesias-Chiesa JM, Romero-Antonio Y, Chávez-Cortes C, Gay-Molina JG, et al. (2011) [Cost-effectiveness in the detection of influenza H1N1: clinical data versus rapid tests]. Rev Panam Salud Publica 29: 1-8.
24. Halder N, Kelso JK, Milne GJ, (2011) Cost-effective strategies for mitigating a future influenza pandemic with H1N1 2009 characteristics. PLoS One 6: e22087.
25. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK, (2009) Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med 151: 829-839.
26. Khazeni N, Hutton DW, Garber AM, Owens DK, (2009) Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Ann Intern Med 151: 840-853.
27. Lee BY, Bailey RR, Wiringa AE, Assi TM, Beigi RH, (2009) Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model. Obstet Gynecol 114: 971-980.
28. Lee BY, Brown ST, Korch GW, Cooley PC, Zimmerman RK, et al. (2010) A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 28: 4875-4879.
29. Lee BY, McGlone SM, Bailey RR, Wiringa AE, Zimmer SM, et al. (2010) To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling. PLoS One 5: e11284.
30. Lee BY, Bacon KM, Donohue JM, Wiringa AE, Bailey RR, et al. (2011) From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine 29: 2149-2158.
31. Lee BY, Tai JH, Bailey RR, McGlone SM, Wiringa AE, et al. (2011) Economic model for emergency use authorization of intravenous peramivir. Am J Manag Care 17: e1-9.
32. Lee VJ, Phua KH, Chenm MI, Chow A, Ma S, et al. (2006) Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore. Emerg Infect Dis 12: 95-102.
33. Lee VJ, Tok MY, Chow VT, Phua KH, Ooi EE, et al. (2009) Economic analysis of pandemic influenza vaccination strategies in Singapore. PLoS One 4: e7108.
34. Lu CJ, Luo Y, Zhou H, Qin XL, Chen BJ, et al. (2010) A preliminary study on the medical expenditure of Chinese medicine and integrative medicine treatment for influenza A (H1N1) in the fever clinics. Chin J Integr Med 16: 493-497.
35. Lugnér AK, Postma MJ, (2009) Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Eur J Public Health 19: 516-520.
36. Lugnér AK, Mylius SD, Wallinga J, (2010) Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ 19: 518-531.
37. Medema JK, Zoellner YF, Ryan J, Palache AM, (2004) Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply. Virus Res 103: 9-15.
38. Mota NV, Lobo RD, Toscano CM, Pedroso de Lima AC, Souza Dias MB, et al. (2011) Cost-effectiveness of sick leave policies for health care workers with influenza-like illness, Brazil, 2009. Emerg Infect Dis 17: 1421-1429.
39. Newall AT, Wood JG, Oudin N, MacIntyre CR, (2010) Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies. Emerg Infect Dis 16: 224-230.
40. Perlroth DJ, Glass RJ, Davey VJ, Cannon D, Garber AM, et al. (2010) Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States. Clin Infect Dis 50: 165-174.
41. Piercy J, Miles A, (2003) The economics of pandemic influenza in Switzerland Bern, Switzerland Federal Office of Public Health.
42. Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, et al. (2011) Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. PLoS One 6: e22308.
43. Sander B, Hayden FG, Gyldmark M, Garrison LP Jr, (2006) Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics 24: 373-386.
44. Sander B, Bauch C, Fisman DN, Fowler R, Kwong JC, et al. (2009) Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Early evidence from the Canadian experience. PLoS Curr 1: RRN1137.
45. Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, et al. (2009) Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 12: 226-233.
46. Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, et al. (2010) Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine 28: 6210-6220.
47. Siddiqui MR, Edmunds WJ, (2008) Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis 14: 267-274.
48. Smetanin PKP, Stiff D, Sherman G, Briante C, (2009) Contrast of prophylactically protecting Canadian health care workers and emergency service providers: a moderate Canadian pandemic mathematical assessment. RiskAnalytica report Toronto, Canada RiskAnalytica.
49. Smetanin P, Stiff D, Briante C, (2010) H1N1 2009 pandemic analysis: evaluation and scenarios for post pandemic planning. RiskAnalytica report Toronto, Canada RiskAnalytica.
50. Tracht SM, del Valle SY, Edwards B, (2011) Economic analysis of the use of facemasks during pandemic (H1N1) 2009 Los Alamos, US Los Alamos National Laboratory.
51. Yarmand H, (2010) Cost-effectiveness analysis of vaccination and self-isolation in case of an H1N1 outbreak [Dissertation] Raleigh, US North Carolina State University.
52. World Health Organization (2005) WHO checklist for influenza pandemic preparedness planning Geneva, Switzerland Department of Communicable Disease Surveillance and Response, Global Influenza Programme, World Health Organization.
53. Dutta A, (2008) The effectiveness of policies to control a human influenza pandemic: a literature review. Policy research working paper Washington DC, US World Bank.
54. Walker DG, Hutubessy R, Beutels P, (2010) WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 28: 2356-2359.
55. Anderson R, Shemilt I, (2010) The role of economic perspectives and evidence in systematic review. In: Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, editors. Evidence-based decisions and economics: health care, social welfare, education and criminal justice, 2nd ed Oxford, UK Wiley-Blackwell.
56. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, et al. (2009) Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 12: 409-418.
57. Lugnér AK, Postma MJ, (2009) Mitigation of pandemic influenza: review of cost-effectiveness studies. Expert Rev Pharmacoecon Outcomes Res 9: 547-558.
58. Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL, eds. (2005) Methods for the economic evaluation of health care programmes. 3rd ed Oxford (UK).